Oncological and peri-operative outcomes of percutaneous cryoablation of renal cell carcinoma for patients with hereditary RCC diseases – An analysis of European multi-centre prospective EuRECA registry
Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK)
STARLITE 2: Phase 2 study of nivolumab plus 177lutetium-labeled anti–carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab (177Lu-girentuximab) in patients (pts) with advanced clear cell renal cell carcinoma (ccRCC)